Ascletis Pharma Advances in Obesity Treatment with ASC37 Development

Ascletis Pharma Inc., listed on the Hong Kong Stock Exchange, is a leading biotechnology company focused on the development and commercialization of innovative treatments for metabolic diseases. The company has recently made a significant breakthrough by selecting ASC37, its first oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development, aiming to address the growing needs in obesity treatment.Key Insights:ASC37, developed with Ascletis' proprietary Peptide Oral Transport ENhancement Technolog ...